CTI BioPharma Corp. (NASDAQ:CTIC) is scheduled to be announcing its earnings results after the market closes on Tuesday, February 14th. Analysts expect the company to announce earnings of ($0.65) per share for the quarter.
Shares of CTI BioPharma Corp. (NASDAQ:CTIC) opened at 4.62 on Monday. The company’s market cap is $129.36 million. CTI BioPharma Corp. has a 12 month low of $3.07 and a 12 month high of $7.60. The stock has a 50 day moving average of $4.23 and a 200-day moving average of $1.30.
Separately, Zacks Investment Research cut CTI BioPharma Corp. from a “buy” rating to a “hold” rating in a research note on Wednesday, November 2nd.
COPYRIGHT VIOLATION WARNING: “CTI BioPharma Corp. (CTIC) to Release Quarterly Earnings on Tuesday” was posted by sleekmoney and is the sole property of of sleekmoney. If you are viewing this article on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this article can be read at http://sleekmoney.com/cti-biopharma-corp-ctic-to-release-quarterly-earnings-on-tuesday/1657733.html.
CTI BioPharma Corp. Company Profile
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/cti-biopharma-corp-ctic-to-release-quarterly-earnings-on-tuesday/1657733.html
Receive News & Ratings for CTI BioPharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma Corp. and related companies with MarketBeat.com's FREE daily email newsletter.